c-Met receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-10. Numbers and descriptions here follow the published literature rather than marketing material.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
At Trump's direction, the United States has executed a series of airstrikes in the Caribbean Sea on vessels alleged to be smuggling illegal drugs. As of January 4, 2026, a total of 35 strikes have been conducted, in which 115 individuals have been killed and 2 have been rescued after surviving the strikes. Since the first strike, which was conducted on September 2, 2025, and killed eleven people, the Trump Administration has invoked combatting "terrorism" conducted by drug cartels as a justification for the strikes. Many legal experts have argued that the strikes constitute illegal extrajudicial killings under both U.S. and international law, noting that drug smuggling is generally considered to be a crime, not an act of war, and that the military is categorically prohibited from targeting civilians, even suspected criminals, unless facing a threat of imminent harm. Conservative lawyer and commentator Andrew C. McCarthy, writing in National Review, called the strikes "lawless" and "not legitimate under the law". The U.S. Department of Justice's Office of Legal Counsel defended the strikes in a memo that has not been released to the public, endorsing President Trump's claim that the United States is an armed conflict with Latin American drug cartels and arguing that the destruction of drug boats eliminates a source of revenue that could be used to purchase weapons for attacks against the United States.
In October 2019, GSK agreed to sell its rabies vaccine, RabAvert, and its tick-borne encephalitis vaccine, Encepur, to Bavarian Nordic for US$1.06 billion (€955 million). In July 2020, GSK acquired a 10% stake in German biotech company CureVac.
In most modern ("boosted") thermonuclear weapons, fusion directly provides only a small fraction of the total energy. Fission of a natural uranium-238 tamper by fast neutrons produced from D–T fusion accounts for a much larger (i.e. boosted) energy release than the fusion reaction itself.
Sources: en.wikipedia.org
==== 2019 ==== The lifespan of Caenorhabditis elegans (free-living nematodes) was increased by 5–6 times (by 400–500%) using simultaneous impact in IIS and TOR pathways. This is equivalent to how a human would live 400–500 years. The study was done by the MDI Biological Laboratory in collaboration with the Buck Institute for Research on Aging and Nanjing University. Scientists at the Mayo Clinic report the first successful use of senolytics, a new class of drug with potential anti-aging benefits, to remove senescent cells from human patients with a kidney disease. By combining doses of lithium, trametinib and rapamycin into a single treatment, researchers extend the lifespan of fruit flies (Drosophila) by 48%. Researchers at Harvard Medical School identify a link between neural activity and human longevity. Neural excitation is linked to shorter life, while suppression of overactivity appears to extend lifespan. Scientists at the Riken Center for Integrative Medical Sciences and Keio University use single-cell RNA analysis to find that supercentenarians have an excess of cytotoxic CD4 T-cells, a type of immune cell. This phenomenon was first demonstrated in mice
Galloway told The Independent on Sunday in June 2012: "I am not a pacifist. I am a revolutionary. I am a Socialist who doesn't like Capitalism and who likes Imperialism less. ... I support the armed struggle where there is no alternative." In a 2002 interview with The Guardian, Galloway said he had supported the Soviet Union and said that its end was "the biggest catastrophe of my life". By 2013, he described himself on Twitter as "pro-Palestine, anti-war, pro-equality, anti-Islamophobia". In 2024, Galloway identified as socially conservative, and in 2025 he said he "no longer want[s] to hear [himself] described as a leftist", adding that "it now means liberalism, licence, ‘refugees welcome here’ and so on. All this is inimical to the interests of the working class". Writing for The Guardian in 2024, Michael Chessum argued that Galloway's politics had shifted in the latter half of the 2010s, embracing Scottish unionism and social conservatism alongside more typically leftist positions, and highlighting the involvement of the socially conservative Communist Party of Great Britain (Marxist–Leninist) in the early years of the Workers Party. Chessum likened Galloway's political evolution to that of German politician Sahra Wagenknecht, a leading member of The Left who broke away to found her own eponymous political movement, and who similarly espouses socially conservative positions and anti-NATO views.
This exclusion is to ensure that a blended Scotch whisky produced from single malt(s) and single grain(s) distilled at the same distillery does not also qualify as single malt Scotch whisky or single grain Scotch whisky. Nearly 90% of the bottles of Scotch sold per year are blended whiskies. Three types of blends are defined for Scotch whisky:
TMA is a low-potency serotonin 5-HT2A receptor partial agonist, with an affinity (Ki) of >12,000 nM, an EC50Tooltip half-maximal effective concentration of 1,700 nM, and an EmaxTooltip maximal efficacy of 40%. Conversely, it was inactive at the serotonin 5-HT1A, 5-HT2B and 5-HT2C receptors and at several other receptors, at least at the assessed concentrations (up to 10,000 nM). It showed affinity for the mouse and rat trace amine-associated receptor 1 (TAAR1) (Ki = 1,800 nM and 3,200 nM, respectively), whereas it was inactive at the human TAAR1 (EC50 > 10,000 nM). TMA is also a very low-potency serotonin releasing agent (SRA), with an EC50 value of 16,000 nM. In contrast, it is inactive as a releasing agent and reuptake inhibitor of dopamine and norepinephrine (EC50 > 100,000 nM). Despite its apparent SRA activity in vitro, TMA did not increase brain serotonin or dopamine levels in rodents in vivo. TMA is similarly inactive as a monoamine oxidase inhibitor (MAOI), including of both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) (IC50Tooltip half-maximal inhibitory concentration > 200,000 nM). The low potency of TMA as a serotonin 5-HT2A receptor agonist is analogous to the case of mescaline, which is a well-known and widely used psychedelic but is likewise a very low-potency agonist of this receptor, showing an affinity (Ki) of 9,400 nM, an EC50 of 10,000 nM, and an Emax of 56% in the same study. For comparison, DOM has shown an affinity (Ki) of 88 nM and an EC50 of 4 to 24 nM.
Sources: en.wikipedia.org
=== 2019 Seattle, Washington, United States === Thirteen people were exposed to caesium-137 in May 2019 at the Research and Training building in the Harborview Medical Center complex in Seattle, Washington. A contract crew was transferring the caesium from the lab to a truck when the powder was spilled. Five people were decontaminated and released, but eight who were more directly exposed were taken to the hospital while the research building was evacuated.
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, monoclonal antibodies, and living medicines used in cell therapy. Biopharmaceuticals can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine. Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. The term biologics is often used more restrictively to mean biopharmaceuticals that are produced using recombinant DNA technology. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Biopharmaceutics is pharmaceutics that works with biopharmaceuticals. Biopharmacology is the branch of pharmacology that studies biopharmaceuticals.
=== Plants === Carnivorous plants can survive without eating prey. Catching insects, however, supports their growth. Mushrooms, molds, and other fungi are not plants, despite similarities in their morphology and lifestyle. The historical classification of fungi as plants is defunct, and although they are still commonly included in botany curricula and textbooks, modern molecular evidence shows that fungi are more closely related to animals than to plants. Poinsettias are not highly toxic to humans or cats. While it is true that they are mildly irritating to the skin or stomach, and may sometimes cause diarrhea and vomiting if eaten, they rarely cause serious medical problems. Sunflowers do not always point to the Sun. Flowering sunflowers face a fixed direction (often east) all day long, but do not necessarily face the Sun. However, in an earlier developmental stage, before the appearance of flower heads, the immature buds do track the Sun (a phenomenon called heliotropism).
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.